Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib in Recurrent IDH 1/2 Gliomas
NCT05406700Phase 1Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- May 2023
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of niraparib in glioma (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Drug concentration of niraparib at 1 year. Started May 2023; status: active, not recruiting.
02
Drugs
niraparib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT05406700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05406700.